NASDAQ:ALECAlector Stock Price, Forecast & News

Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC shares have decreased by 42.4% and is now trading at $14.35.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Alector.

Alector Inc (NASDAQ:ALEC) issued its earnings results on Tuesday, August, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.09. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%.
View Alector's earnings history.

8 Wall Street analysts have issued 12-month target prices for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they anticipate Alector's stock price to reach $32.80 in the next year. This suggests a possible upside of 128.6% from the stock's current price.
View analysts' price targets for Alector.

Media headlines about ALEC stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alector earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Alector.

Alector saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 5,630,000 shares, an increase of 12.6% from the January 31st total of 5,000,000 shares. Based on an average daily trading volume, of 593,100 shares, the days-to-cover ratio is presently 9.5 days. Currently, 12.6% of the company's stock are short sold.
View Alector's Short Interest.

Some companies that are related to Alector include Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Legend Biotech (PCVX) and Mesoblast (MESO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Heron Therapeutics (HRTX), NVIDIA (NVDA), Pfizer (PFE), LogicBio Therapeutics (LOGC), Tcr2 Therapeutics (TCRR) and Crispr Therapeutics (CRSP).

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.24%), Goldman Sachs Group Inc. (0.70%), Cannell Peter B & Co. Inc. (0.26%), First Trust Advisors LP (0.18%), Alps Advisors Inc. (0.14%) and California Public Employees Retirement System (0.13%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Russell Investments Group Ltd., Principal Financial Group Inc., Cannell Peter B & Co. Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney, and Terrance Mcguire.
View insider buying and selling activity for Alector.

ALEC stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Swiss National Bank, First Trust Advisors LP, Goldman Sachs Group Inc., California Public Employees Retirement System, Barclays PLC, Rafferty Asset Management LLC, and New York State Common Retirement Fund. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $14.35.

Alector has a market capitalization of $1.13 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

The official website for Alector is www.alector.com.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]